Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 20/20 | 0.73 |
| ▸ | PTGDR | Q13258 | 15/20 | 0.73 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.53 |
| ▸ | PTGFR | P43088 | 1/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12923780 | 0.88 | TBXA2R (0.61) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL990995 | 0.85 | TBXA2R (0.73) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL990588 | 0.85 | TBXA2R (1.00) | TBXA2RPTGDR | |
| SCHEMBL1255608 | 0.83 | TBXA2R (0.54) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL2922261 | 0.83 | TBXA2R (0.55) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL4466127 | 0.82 | TBXA2R (0.79) | TBXA2RPTGDR | |
| SCHEMBL13122993 | 0.81 | TBXA2R (0.80) | TBXA2RPTGDR | |
| SCHEMBL10312763 | 0.79 | TBXA2R (0.74) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL4321145 | 0.77 | TBXA2R (0.62) | TBXA2RPTGDRPTGER1PTGFRPTGER3 | |
| SCHEMBL5079585 | 0.76 | TBXA2R (0.79) | TBXA2RPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | CHENG KANG | 2010-03-25 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070299122-A1 | Method of Treating Pathological Blushing | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | MERCK & CO., INC. | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299122-A1 | Method of Treating Pathological Blushing | BDKRB2, BDKRB1, PTGIR | TBXA2R 9/4885PTGDR 11/4885PTGER1 15/4885 |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | TBXA2R 53/4885PTGDR 518/4885PTGER1 258/4885 |
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | LDLR, LPAR5, FFAR1 | TBXA2R 44/4885PTGDR 164/4885PTGER1 129/4885 |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | TBXA2R 44/4885PTGDR 591/4885PTGER1 268/4885 |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | LDLR, LIPA, APOB | TBXA2R 68/4885PTGDR 97/4885PTGER1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.